NEW YORK (GenomeWeb News) — Thallion Pharmaceuticals said today it has sold 80 percent of its stake in its Caprion Proteomics business to a company owned by Great Point Partners, while Thallion will retain the remaining 20 percent of the company.
 
The deal will leave the new company, which will be called Caprion Proteomics, owning “substantially all" of Thallion’s proteomics assets, including the CellCarta platform. It will adopt $22.2 million in Thallion’s long-term debt obligations.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.